Center for Cancer Experimental Therapeutics

描述(由申请人提供)： 这项提议的目标是继续并扩大现有的“科布雷癌症实验治疗中心”。堪萨斯大学劳伦斯分校(KU)、堪萨斯州立大学医学中心(KUMC)、堪萨斯州立大学(KSU)和威奇托州立大学(WSU)四所州立机构联合资源和教职员工建立了一个中心，指导与癌症相关的研究的初级教师，并创建在化学和生物学之间进行实验所需的新基础设施。请拨资金支持五个项目。项目调查人员与成熟的、活跃的高级教员合作，他们将担任他们的导师。此外，还将设立竞争性第一奖励计划，以增强未来应聘者的竞争力，并设立创业强化一揽子计划。来自堪萨斯大学和堪萨斯技术企业公司(KTEC)的支持以及NIH-Cobre基金将继续为两个现有的核心设施和一个新的核心设施提供支持。两个Cobre核心--药物化学和高通量筛选--将继续得到支持，这两个核心是在上一个授权期开始的。将建立一个新的核心设施，用于产生转基因和敲除动物。需要这些核心来确定新的生物靶点和新的生物活性化合物，这些将是有用的基础生物医学研究工具，以及潜在的治疗剂。核心设施将由一群经验丰富的研究人员运营，他们在药物和组合化学、细胞和分子生物学、生物化学、癌细胞生物学、药理学以及用于化合物和细胞目标识别的新型生物测试开发方面具有专业知识。识别新药物靶标、产生和分析新化合物的专业知识，以及开发用于筛选的生物分析的专业知识相结合，为多学科研究提供了独特的机会。在授权期结束时，该中心将成为KU-Lawrence与KU-Lawrence和KU医学中心联合成立的新癌症中心的一部分。这三个科布雷核心实验室将成为大学支持的研究服务实验室。

DESCRIPTION (provided by applicant): The goal of this proposal is to continue and expand the existing "COBRE Center for Cancer Experimental Therapeutics." Four state institutions the University of Kansas-Lawrence (KU), the KU Medical Center (KUMC), Kansas State University (KSU), and Wichita State University (WSU), combine resources and faculty to establish a Center to mentor junior faculty in cancer-related research and to create novel infrastructure needed for experimentation at the interface between chemistry and biology. Funds are requested for the support of five projects. Project investigators are partnered with established, active, senior faculty who will serve as their mentors. In addition, the competitive First Award Program to enhance the competitiveness of future recruits, and a program for start-up enhancement packages will be established. Support from the University of Kansas and the Kansas Technology Enterprise Corporation (KTEC) together with NIH-COBRE funding will provide continued backing for two existing Core facilities and a new Core. Two COBRE Cores, Medicinal Chemistry and High Throughput Screening, started in the last granting period, will receive continued support. A new Core facility for the generation of transgenic and knock-out animals will be established. These Cores are needed to identify novel biological targets, and novel bioactive compounds, that will be useful basic biomedical research tools, and potential therapeutic agents. The Core facilities will be operated by an experienced group of investigators with expertise in the areas of medicinal and combinatorial chemistry, cell and molecular biology, biochemistry, cancer cell biology, pharmacology and the development of novel bioassays for compound and cellular target identification. The combination of expertise for the identification of novel drug targets, generation and analysis of novel compounds, together with that for the development of bioassays for screening, offers a unique opportunity for multidisciplinary research. At the end of the granting period, the Center will be the KU-Lawrence part of a new joint Cancer Center with KU-Lawrence and the KU Medical Center. The three COBRE Core laboratories will become University-supported research service laboratories.